Abstract
A novel testing policy was implemented in May in France to systematically screen potential COVID-19 infections and suppress local outbreaks while lifting lockdown restrictions. 20,777 virologically-confirmed cases were notified in mainland France from May 13, 2020 (week 20, end of lockdown) to June 28 (week 26). Accounting for missing data, positive tests before symptom onset, and the delay from symptom onset to test, this corresponds to 14,061 [95% CI 13,972-14,156] cases with symptom onset during this period, a likely underestimation of the real number. Using age-stratified transmission models parameterized to behavioral data and calibrated to regional hospital admissions, we estimated that 103,907 [95% CI 90,216-116,377] COVID-19 symptomatic cases occurred, suggesting that 9 out of 10 cases with symptoms were not ascertained. Median detection rate increased from 7% [6-8]% to 38% [35-44]% over time, with large regional variations. Healthcare-seeking behavior in COVID-19 suspect cases remained low (31%). Model projections for the incidence of symptomatic cases (6.7 [5.8, 7.4] per 100,000 in week 26) were compatible with estimates from participatory surveillance, provided that 80% of suspect cases consulted. Encouraging awareness and same-day healthcare-seeking behavior in suspect cases is critical to improve detection. The capacity of the system remained however insufficient even at the low levels of viral circulation achieved after lockdown, and was predicted to deteriorate rapidly for increasing epidemic activity. Substantially more aggressive, targeted, and efficient testing with easier access is required to act as a pandemic-fighting tool. These elements should be considered in light of the currently observed increase of cases in France and other European countries.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was partially supported by ANR project DATAREDUX (ANR-19-CE46-0008-03) and EVALCOVID-19 (ANR-20- 706 COVI-0007); EU H2020 grants MOOD (H2020-874850) and RECOVER (H2020-101003589); REACTing COVID-19 modeling and surveillance grants.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
GrippeNet.fr/COVIDnet.fr was reviewed and approved by the French Advisory Committee for research on information treatment in the health sector (i.e. CCTIRS, authorization 11.565), and by the French National Commission on Informatics and Liberty (i.e. CNIL, authorization DR-2012-024) - the authorities ruling on all matters related to ethics, data, and privacy in the country.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available at the references cited.
